IDEAYA Biosciences, Inc.
Ideaya Biosciences, Inc. (NASDAQ: IDYA) is a precision medicine oncology company committed to discovering, developing, and commercializing transformative therapies for cancer. The company integrates expertise in small-molecule drug discovery, structural biology, and bioinformatics with internal capabilities in… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What IDEAYA Biosciences, Inc. does
In the company’s own words
Ideaya Biosciences, Inc. (NASDAQ: IDYA) is a precision medicine oncology company committed to discovering, developing, and commercializing transformative therapies for cancer. The company integrates expertise in small-molecule drug discovery, structural biology, and bioinformatics with internal capabilities in identifying and validating translational biomarkers to develop targeted therapies aligned to the genetic drivers of disease. Ideaya's approach focuses on developing potentially first-in-class therapeutics through synthetic lethality mechanisms and antibody-drug conjugates for molecularly defined solid tumor indications.
The company's clinical pipeline consists of nine product candidates across four strategic focus areas. Darovasertib, an oral protein kinase C inhibitor, represents the most advanced program and is being evaluated for uveal melanoma across multiple clinical trials in metastatic, neoadjuvant, and adjuvant settings. The company is also advancing combinations of topoisomerase I inhibitor-based antibody-drug conjugates with DNA damage response pathway inhibitors, including IDE849, a DLL3-targeting ADC, and IDE161, a PARG inhibitor. For patients with MTAP-deleted solid tumors, Ideaya is exploring IDE397, a MAT2A inhibitor, in combination with various agents. The pipeline also includes next-generation therapies such as IDE574, targeting KAT6/7, and IDE275, targeting Werner helicase.
Ideaya has established strategic collaborations with leading pharmaceutical companies including Pfizer, Gilead Sciences, Novartis, and Servier to support clinical development and commercialization efforts. In August 2025, the company entered into an exclusive license agreement with Servier for darovasertib outside the United States, receiving a $210 million upfront payment and eligibility for up to $320 million in milestone payments. The company operates an integrated discovery platform featuring proprietary chemical libraries, structure-based drug design capabilities, and machine-learning tools for molecular design. Ideaya also maintains strategic collaborations with academic institutions including the University of California, San Diego and the Broad Institute for synthetic lethality target discovery and biomarker validation. The company's website is www.ideayabio.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1676725
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns IDEAYA Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · IDEAYA Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do IDEAYA Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of IDEAYA Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in IDEAYA Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”